Cargando…

2410. Clinical Outcomes Associated With Various Treatment Options for Infections Caused by Carbapenem-Resistant Enterobacteriaceae

BACKGROUND: Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) have been designated an urgent level threat to public health. With the advent of novel β lactam/β-lactamase inhibitor combinations, the armamentarium against CRE is expanding. Our study aims to evaluate clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bandali, Aiman, Deering, Caytlin, Bias, Tiffany, Gancher, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254826/ http://dx.doi.org/10.1093/ofid/ofy210.2063

Ejemplares similares

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

591. Impact of an Antimicrobial Stewardship (ASP) Initiative Evaluating Antiretroviral Regimens for HIV-Positive Patients
por: Nimarko, Kwabena, et al.
Publicado: (2018)

2410. Clinical outcomes and antimicrobial management strategies of Pseudomonas endocarditis
por: Shah, Sunish, et al.
Publicado: (2023)

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
por: Sheu, Chau-Chyun, et al.
Publicado: (2019)

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
por: Morrill, Haley J., et al.
Publicado: (2015)

1193. Comparison of the Clinical Outcomes of Patients With IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenem-Sensitive Enterobacteriaceae in Japan
por: Saito, Sho, et al.
Publicado: (2018)

369 Outcomes of Patients with Carbapenem-Resistant Enterobacteriaceae
por: Raybould, Jillian, et al.
Publicado: (2014)

2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
por: Ahmed, Sara, et al.
Publicado: (2018)

621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates
por: Belal, Maymonah, et al.
Publicado: (2019)

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

Molecular Characterization of Carbapenem-Resistant Enterobacteriaceae in the USA, 2011–2015
por: Ansari, Uzma, et al.
Publicado: (2017)

1826. Impact of Rapid Diagnostics and Ceftazidime–Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae
por: Satlin, Michael J, et al.
Publicado: (2019)

2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital
por: Begum, Khurshida, et al.
Publicado: (2019)

1249. Emergence of Diverse Carbapenem-Resistant Enterobacteriaceae (CRE) in the Dominican Republic
por: Fermin, Rita Rojas, et al.
Publicado: (2018)

Activity of Ceftolozane/tazobactam (C/T) and Ceftazidime/avibactam (CZA) against Extended-spectrum Β-lactamase (ESBL)-producing Enterobacteriaceae and Multidrug-resistant (MDR) Pseudomonas aeruginosa Isolates
por: Hirsch, Elizabeth B, et al.
Publicado: (2017)

1457. Serial Passage of Enterobacteriaceae to Explore Development of Carbapenem Resistance
por: Nissim, Yosef, et al.
Publicado: (2020)

2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
por: Snayd, Mary, et al.
Publicado: (2018)

434 Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies
por: Satlin, Michael J., et al.
Publicado: (2014)

Factors Associated with Mortality in Carbapenem-Resistant Enterobacteriaceae Bacteremia: Focus on Antibiotic Therapy
por: Pillinger, Kelly E, et al.
Publicado: (2017)

1194. Carbapenem-Resistant Enterobacteriaceae in Kentucky: Initial 6 Months of Mechanism Testing
por: Spicer, Kevin, et al.
Publicado: (2018)

533. Impact of Different Definitions on Reported Rates of Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Passaretti, Catherine, et al.
Publicado: (2019)

2145. Carbapenem-Resistant Enterobacteriaceae infections at the Maharaj Nakorn Chiang Mai Hospital
por: Chaiwarith, Romanee, et al.
Publicado: (2019)

509. The Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) in a Community Hospital Setting
por: Lewis, Sally, et al.
Publicado: (2019)

417. Factors associated with 30-day Mortality in Carbapenems-resistant Enterobacteriaceae Infections
por: Osaithai, Naphol, et al.
Publicado: (2022)

Carbapenem Resistant Enterobacteriaceae infections in Houston, Texas: An outline
por: Rehman, Hafeez, et al.
Publicado: (2017)

Resistance Pattern of Carbapenem on Enterobacteriaceae
por: Pokharel, Khilasa, et al.
Publicado: (2018)

2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
por: Durante, Amanda, et al.
Publicado: (2018)

354 Six Months of Surveillance for Carbapenem-Resistant Enterobacteriaceae in Maryland
por: Vaeth, Elisabeth, et al.
Publicado: (2014)

1441. Using Carbapenem Resistance Levels to Discriminate Between Carbapenemase Producing and Non-Carbapenemase Producing Carbapenem Resistant Enterobacteriaceae
por: Koehne, William J, et al.
Publicado: (2020)

Aminoglycoside Susceptibility Agreement between an Automated System and Broth Microdilution for Carbapenem-resistant Enterobacteriaceae
por: Kulengowski, Brandon, et al.
Publicado: (2017)

631. Laboratory Surveillance of Carbapenem-Resistant Enterobacteriaceae in an Endemic Country, Greece, 2015–2018
por: Tryfinopoulou, Kyriaki, et al.
Publicado: (2019)

1964. Microbiological Outcomes With Plazomicin (PLZ) vs. Colistin (CST) in Patients With Bloodstream Infections (BSI) Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) in the CARE Study
por: Serio, Alisa W, et al.
Publicado: (2018)

Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?
por: Lodise, Thomas, et al.
Publicado: (2017)

Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
por: Yamamoto, Michele, et al.
Publicado: (2014)

Therapeutic Options for the Treatment of Carbapenem-resistant Enterobacteriaceae Infections: Hope in the Times of Hype and Despair
por: Ansari, Abdul S
Publicado: (2021)

Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Zhu, Yunying, et al.
Publicado: (2021)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

2450. Antibiotic Treatment for Carbapenem-Resistant Enterobacteriaceae (CRE) and Outcomes in Veterans With Spinal Cord Injury/Disorder (SCI/D)
por: Little, Erica K, et al.
Publicado: (2018)

132. Carbapenem-resistant Enterobacteriaceae colonization in a Neonatal Intensive Care Unit in Bogotá, Colombia: Characterization and clinical outcomes
por: Londono-Ruiz, Juan Pablo, et al.
Publicado: (2022)

Epidemiologic Review of Carbapenem-Resistant Enterobacteriaceae and Duodenoscopes in the Department of Veterans Affairs
por: Ryono, Russell, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bj5mdmihomo4uikme00gqg7s33